Ceva and Sogeval, a subsidiary of Sofiproteol, announced Dec. 6 the opening of exclusive negotiations to create a future alliance.
The management teams of the two French companies are looking into a strategic alliance that would give them a strong position among the world leaders in animal health.
Sogeval specialises in the development, manufacture and marketing of veterinary drugs and speciality products. The firm has been growing steadily and now plays a major role in the prevention and treatment of diseases in both companion animals and livestock. The company operates internationally through three subsidiaries in the U.S., U.K. and Denmark as well as a network of more than 60 distributors worldwide.
Ceva focused on the research, development, production and marketing of pharmaceutical products and vaccines for companion animals, ruminants, pigs and poultry. Ceva is directly present in 43 countries and has active business in more than 110 countries.
According to the announcement, the two companies have strong complementarities bot the companion animal and livestock production sectors. For example, Ceva and Sogeval have developed similar expertise in two areas cardiology and pain management in companion animals. Both also have significant expertise in the development and formulation of antibiotics, vaccines and reproductive products for livestock, the announcement said.
Spgeval parent company Sofiproteol will continue its development of biosecurity and nutritional products, which the proposed alliance with Ceva will give the benefit of an international partner.